XNAS
NAGE
Market cap271mUSD
Jul 09, Last price
3.49USD
1D
3.56%
1Q
-22.44%
Jan 2017
5.44%
IPO
-61.22%
Name
Chromadex Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ChromaDex Corporation is a bioscience enterprise committed to advancing healthy aging. The company's operations are segmented into three primary areas: Consumer Products, Ingredients, and Analytical Reference Standards and Services. Its research efforts largely concentrate on nicotinamide adenine dinucleotide (NAD+). Under its Consumer Products division, ChromaDex provides finished dietary supplements, which incorporate its proprietary ingredients, directly to consumers and through distributors. A flagship offering is TRU NIAGEN, a supplement featuring NIAGEN, the company's proprietary nicotinamide riboside (an NAD+ precursor) as its active component. The Ingredients segment is responsible for the development and commercialization of specialized ingredient technologies. It supplies these unique raw materials, including NIAGEN, to other manufacturers for use in their consumer products. Another significant ingredient is IMMULINA, composed of Braun-type lipoproteins and spirulina extracts, which is designed to support immune system function. Additionally, ChromaDex offers analytical reference standards and services. These products are vital for performing quality control checks on raw materials and finished goods within industries such as dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceuticals. TRU NIAGEN products reach consumers via multiple channels, including ChromaDex's dedicated e-commerce site, TRUNIAGEN.com, as well as Amazon and other online marketplaces. Distribution also extends to specialty retailers and directly to healthcare practitioners within the United States. ChromaDex Corporation's main office is located in Los Angeles, California.
IPO date
Jun 25, 2007
Employees
113
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||